search
Back to results

Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

Primary Purpose

Hypogonadism

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
TFG capsules (200 mg /capsule)
Placebo oral capsule
Sponsored by
Pusan National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypogonadism focused on measuring Herbal medicine, phytotherapy, testosterone

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • total scores on the Aging Males' Symptoms scale (AMS) questionnaire ≥ 27; total serum cholesterol <220 mg/dl; and triglyceride 150-399 mg/dl

Exclusion Criteria:

  • diagnosis of another sexual disorder, serum creatinine > 2.5 mg/dL, an uncontrolled psychiatric disorder, history of major hematological, renal, or hepatic abnormalities, body mass index ≥ 45 kg/m2, HBsAg (hepatitis B surface antigen) positive, prostate specific antigen (PSA) ≥ 4.0 ng/ml, cardiac failure, or a history of alcoholism or substance abuse. Patients who had taken PDE5 inhibitors, TRT, anti-androgen, statins, fibrates, niacin, steroid, fish oil, colestin, fiber-based laxatives, phytosterol margarines, anti-diabetics, anti-platelet, thyroxine, diuretics, or beta-blockers were also excluded.

Sites / Locations

  • Department of Urology, Pusan National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

fenugreek seed and Lespedeza cuneata (TFG)

Placebo

Arm Description

Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake

Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake

Outcomes

Primary Outcome Measures

Aging Males' Symptoms (AMS) scale
level of serum total testosterone
level of serum free testosterone
Aging Males' Symptoms (AMS) scale
level of serum total testosterone
level of serum free testosterone

Secondary Outcome Measures

percentage of positivity on the Androgen Deficiency in Aging Males (ADAM) questionnaire
level of serum total cholesterol
level of serum HDL-C
level of serum LDL-C
level of serum triglyceride
perceived stress scale (PSS)-10
Scores of the International Index of Erectile Function (IIEF)

Full Information

First Posted
February 11, 2017
Last Updated
February 17, 2017
Sponsor
Pusan National University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03057899
Brief Title
Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS
Official Title
Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
June 2015 (Actual)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pusan National University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Objective: The aim of this study was to investigate the efficacy and safety of a mixed extract of fenugreek seed and Lespedeza cuneata (TFG) for the treatment of testosterone deficiency syndrome (TDS). Design: Patients were instructed to take a placebo capsule or 200 mg TFG capsule twice per day for 8 weeks. Outcome measures: The primary efficacy variable was the change from baseline in the Aging Males' Symptoms scale (AMS), as well as levels of serum total testosterone and free testosterone. Secondary efficacy measurements included changes from baseline in the number of 'yes' answers on the Androgen Deficiency in the Aging Male questionnaire (ADAM), levels of serum total cholesterol, HDL-C, LDL-C, triglyceride, perceived stress scale (PSS-10), all domain scores of the International Index of Erectile Function (IIEF), as well as changes in body composition.
Detailed Description
Testosterone deficiency syndrome (TDS) is "a clinical and biochemical syndrome associated with advancing age and characterized by symptoms of a deficiency in serum testosterone levels". TDS can cause a significant decrease in quality of life and has many adverse effects on multiple organs in terms of men's health. In addition to the detrimental effect of sexual functions, men with TDS tend to have increased waist circumference, hyperglycemia, hypertriglyceridemia, hyperlipidemia, and a history of diabetes. TDS can be treated with testosterone replacement therapy (TRT). TRT should be initiated on an individualized basis in TDS patients who have clinical signs and symptoms of androgen deficiency if the benefits of treatment appear to outweigh the potential risks and only after thorough discussion with the patient. Different preparations of testosterone are currently available. The majority of clinical data shows that TRT is very safe and effective. There is currently no evidence that testosterone treatment increases the risk of prostate disease using modern guidelines. However, the fear of prostate cancer and the risk of erythrocytosis may represent the main limitations of TRT in aging men. Additionally, TRT cannot improve the function of Leydig cells (which produce testosterone), but only compensate for the lack of testosterone. Limited research has focused on the use of herbal medicine to improve male health, particularly to increase testosterone levels and support healthy sexual function. Despite the increasing availability of effective conventional medical treatments, plant-derived and herbo-mineral remedies continue to be a popular alternative for men seeking to improve sexual function. Trigonella foenum-graecum Linn, also known as fenugreek, is an aromatic annual plant that reaches heights of 30-60 cm. It is found wild in Kashmir, Punjab, and the upper Gangetic plains, and is widely cultivated in many parts of India. It is used internally as an abortifacient, antispasmodic, appetite stimulant, blood cleanser, laxative, tonic, and expectorant. It is also indicated externally for abscesses, boils, galactagogue, and for its demulcent and emollient properties. The seeds contain diosgenin along with three minor steroidal saponins (similagenin, savsalpogenin, and yuccagenin), choline, trimethylamine (a sex hormone in frogs), vitamins (A, B2, B6, B12, D), lysine, l-tryptophan rich proteins, mucilaginous fiber, coumarin, fenugreekine, nicotinic acid, sapogenins, phytic acid, scopletin and trigonelline, calcium, iron, β-carotene, and other vitamins and essential oils. Previous studies have suggested that Trigonella foenum-graecum seed extract has positive effects on sexual health and quality of life, and that it demonstrates anabolic and androgenic activity in young patients. It is believed that these positive effects are due to increased testosterone, including free testosterone, and that Trigonella foenum-graecum seed extract may be an effective treatment for the symptoms of possible testosterone deficiency in aging men. The basis for this androgenic activity may be due to the fact that Trigonella foenum-graecum seeds contain soluble steroidal saponins, specifically furostanol glycosides, which are responsible for complexing cholesterol in the cell membrane. Other studies have found that Trigonella foenum-graecum increases testosterone and free testosterone, suggesting that it may be an incomplete 5-alpha reductase and aromatase inhibitor. The investigators investigated the efficacy and safety of a mixed extract of Trigonella foenum-graecum seed and lespedeza cuneata (TFG) for the treatment of TDS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypogonadism
Keywords
Herbal medicine, phytotherapy, testosterone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
fenugreek seed and Lespedeza cuneata (TFG)
Arm Type
Experimental
Arm Description
Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
Intervention Type
Drug
Intervention Name(s)
TFG capsules (200 mg /capsule)
Other Intervention Name(s)
mixed extract of fenugreek seed and Lespedeza cuneata (TFG)
Intervention Description
TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo oral capsule
Other Intervention Name(s)
Placebo capsule
Intervention Description
During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
Primary Outcome Measure Information:
Title
Aging Males' Symptoms (AMS) scale
Time Frame
4 week
Title
level of serum total testosterone
Time Frame
4 week
Title
level of serum free testosterone
Time Frame
4 week
Title
Aging Males' Symptoms (AMS) scale
Time Frame
8 week
Title
level of serum total testosterone
Time Frame
8 week
Title
level of serum free testosterone
Time Frame
8week
Secondary Outcome Measure Information:
Title
percentage of positivity on the Androgen Deficiency in Aging Males (ADAM) questionnaire
Time Frame
8 week
Title
level of serum total cholesterol
Time Frame
8 week
Title
level of serum HDL-C
Time Frame
8 week
Title
level of serum LDL-C
Time Frame
8 week
Title
level of serum triglyceride
Time Frame
8 week
Title
perceived stress scale (PSS)-10
Time Frame
8 week
Title
Scores of the International Index of Erectile Function (IIEF)
Time Frame
8 week

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: total scores on the Aging Males' Symptoms scale (AMS) questionnaire ≥ 27; total serum cholesterol <220 mg/dl; and triglyceride 150-399 mg/dl Exclusion Criteria: diagnosis of another sexual disorder, serum creatinine > 2.5 mg/dL, an uncontrolled psychiatric disorder, history of major hematological, renal, or hepatic abnormalities, body mass index ≥ 45 kg/m2, HBsAg (hepatitis B surface antigen) positive, prostate specific antigen (PSA) ≥ 4.0 ng/ml, cardiac failure, or a history of alcoholism or substance abuse. Patients who had taken PDE5 inhibitors, TRT, anti-androgen, statins, fibrates, niacin, steroid, fish oil, colestin, fiber-based laxatives, phytosterol margarines, anti-diabetics, anti-platelet, thyroxine, diuretics, or beta-blockers were also excluded.
Facility Information:
Facility Name
Department of Urology, Pusan National University Hospital
City
Busan
ZIP/Postal Code
602-739
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

We'll reach out to this number within 24 hrs